Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

A Phase II Study of Atezolizumab in Combination with Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1

Active, not recruiting

Conditions: Bladder Cancer
Metastatic Bladder Cancer
Urothelial Carcinoma

Interventions: Drug: Atezolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2016-12-12

Last Posted Date: 2024-10-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT02989584

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States

and more 8 locations

Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC

Phase 1

Terminated

Conditions: Stage IIIA Non-Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Pembrolizumab
Drug: Radiation

First Posted Date: 2016-12-09

Last Posted Date: 2022-12-19

Lead Sponsor: Nathan Pennell, MD, PhD

Target Recruit Count: 9

Registration Number: NCT02987998

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation
Triple-Negative Breast Cancer

First Posted Date: 2016-12-07

Last Posted Date: 2021-07-21

Lead Sponsor: University of Washington

Registration Number: NCT02985658

Locations: 🇺🇸
Seattle Cancer Care Allliance, Seattle, Washington, United States

Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue

Phase 2

Conditions: Squamous Cell Carcinoma
Tongue Neoplasms
Anterior Tongue Squamous Cell Carcinoma

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: 5FU
Radiation: Radiotherapy
Procedure: Glossectomy

First Posted Date: 2016-12-07

Last Posted Date: 2016-12-07

Lead Sponsor: HealthCare Global Enterprise Ltd.

Target Recruit Count: 30

Registration Number: NCT02985255

Locations: 🇮🇳
HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Phase 1

Terminated

Conditions: Follicular Lymphoma Grade III (FL III°)
Mantle Cell Lymphoma (MCL), Blastoid Variant
Aggressive Marginal Zone Lymphoma (MZL)
Diffuse Large B-cell Lymphoma (DLBCL)
Burkitt Lymphoma (BL)

Interventions: Drug: Rituximab
Drug: Cisplatin
Drug: Carboplatin
Drug: Dexamethasone
Drug: Cytarabine
Drug: Lenalidomide
Drug: PegFilgrastim
Procedure: peripheral stem cell collection

First Posted Date: 2016-12-06

Last Posted Date: 2018-01-19

Lead Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Target Recruit Count: 34

Registration Number: NCT02983097

Locations: 🇩🇪
LMU Klinikum München-Großhadern, München, Germany
🇩🇪
Diakonie Krankenhaus Bremen, Bremen, Germany
🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Germany

and more 9 locations

Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)

Phase 2

Completed

Conditions: Lung Adenocarcinoma

Interventions: Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-12-02

Last Posted Date: 2023-07-20

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT02980991

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy

Completed

Conditions: Nonsmall Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Nolbaxol
Drug: Taxotere
Drug: cisplatin

First Posted Date: 2016-11-23

Last Posted Date: 2016-11-23

Lead Sponsor: Yung Shin Pharm. Ind. Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT02972216

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Phase 1

Completed

Conditions: Lung Cancer
Advanced Non-small Cell Lung Cancer
KRAS Gene Mutation

Interventions: Drug: Binimetinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-11-16

Last Posted Date: 2021-07-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 18

Registration Number: NCT02964689

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 1 locations

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Phase 1

Completed

Conditions: Neoplasms

Interventions: Biological: vibostolimab
Biological: pembrolizumab/vibostolimab coformulation
Biological: pembrolizumab
Drug: pemetrexed
Drug: carboplatin
Drug: cisplatin
Drug: etoposide

First Posted Date: 2016-11-15

Last Posted Date: 2024-08-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 470

Registration Number: NCT02964013

Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy

Phase 3

Conditions: Cervical Cancer

Interventions: Radiation: Volumetric Arc Radiotherapy
Radiation: Interstitial brachytherapy
Drug: Cisplatin
Genetic: PIK3CA
Genetic: KRAS
Drug: Gemcitabine
Genetic: BRAF
Genetic: RRM1

First Posted Date: 2016-11-06

Last Posted Date: 2016-11-15

Lead Sponsor: The National Center of Oncology, Azerbaijan

Target Recruit Count: 400

Registration Number: NCT02957266

Locations: 🇦🇿
National Center of Oncology, Baku, Azerbaijan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy